Last reviewed 2026-04-20 · How we verify

Abrocitinib tablet (abrocitinib-tablet)

Abrocitinib tablet, developed by Pfizer Inc., is a marketed drug for moderate to severe atopic dermatitis in adults. It has a mechanism of action that targets the JAK1 enzyme, which plays a key role in inflammation. Abrocitinib has shown clinical differentiation from other treatments due to its efficacy in patients who have had an inadequate response or intolerance to biologics. The commercial significance of Abrocitinib is substantial, with revenue of $63.6B. The pipeline developments for Abrocitinib are focused on its continued use in treating atopic dermatitis. Abrocitinib's mechanism of action and clinical differentiation make it a valuable treatment option for patients with moderate to severe atopic dermatitis.

At a glance

Approved indications

• Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• Live vaccines
• Bacillus Calmette-Guérin (BCG) vaccine
• Other vaccines
• Immunosuppressants
• Methotrexate
• Biologics
• TNF-alpha inhibitors
• Anakinra
• Rituximab
• Other immunosuppressants
• CYP3A4 inhibitors

Key clinical trials

• A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
• Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy (PHASE2)
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (PHASE3)
• Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID (PHASE2)
• A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) (PHASE2)
• Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab (PHASE4)
• A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Abrocitinib tablet CI brief — competitive landscape report
• Abrocitinib tablet updates RSS · CI watch RSS
• Pfizer portfolio CI